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A B S T R A C T
Using prescription drugs during pregnancy is challenging and approached with caution. In this study, we present population-based information on prescription
patterns of benzodiazepines and benzodiazepine-related drugs in the peripartum period. A population-based study of 1,154,817 pregnancies between 1997 and 2015
in Denmark, of which 205,406 (17.8%) pregnancies in women with a psychiatric history. Prescription drugs starting with Anatomical Therapeutic Chemical codes
N05BA, N05CD, and N05CF from 12 months before pregnancy to 12 months following pregnancy were identified. We used generalised estimating equations to
estimate the adjusted 5 year risk difference in the proportion of women redeeming benzodiazepines from 1 year to 5 years after. Logistic regression was used to
analyze the association between characteristics and discontinuation of benzodiazepines during pregnancy. The prevalence of benzodiazepine prescriptions was 1.9%
before pregnancy, 0.6% during pregnancy, and 1.3% after pregnancy. In women with a psychiatric history, the prevalence was 5–6 times higher. A significant
decrease in prescriptions to women with a psychiatric history was observed, which was less profound among women with no psychiatric history. Approximately 90%
of women discontinue benzodiazepines during pregnancy, with a higher percentage of women discontinuing from 1997 to 2015. The observed decrease is likely
explained by changing treatment guidelines.
1. Introduction
The use of prescription drugs during pregnancy is approached with
caution by both pregnant women and their health care professionals,
weighting both fetal and maternal health. Despite this caution, pre-
scribed medication use is common during pregnancy, with estimations
of 27–93% of pregnant women using prescription drugs (Daw et al.,
2011), including benzodiazepines. Benzodiazepines are prescribed for
the treatment of anxiety disorders and also sleep problems (Brunton
et al., 2011). The effects of benzodiazepines are mediated through the
inhibitory neurotransmitter gamma-aminobutyric acid (GABA) (D'Hulst
et al., 2009). Benzodiazepines have anxiolytic, hypnotic, antic-
onvulsant, and muscle relaxant properties, which can relieve symptoms
in the short term (D'Hulst et al., 2009; Donoghue and Lader, 2010).
However, benzodiazepines are highly addictive and guidelines advice
against long term use (Ashton, 1994; Nelson and Chouinard, 1999).
Studies on maternal use of benzodiazepines during pregnancy
mainly focused on adverse birth outcomes. A recent study showed an
increased risk of spontaneous abortion with an odds ratio (OR) of 1.85
(95% confidence interval (CI) 1.61–2.12) (Sheehy et al., 2019). An
increased risk was also found for preterm birth (OR 2.03; 95% CI
1.11–3.69) (Ogawa et al., 2018), cesarian delivery (OR 2.45; 95% CI
1.36–4.40), low birth weight (OR 3.41; 95% CI 1.61–7.26), and use of
neonatal ventilatory support (OR 2.85; 95% CI 1.20 – 6.90) (Yonkers
et al., 2017). Children exposed to benzodiazepines in utero have a
higher chance to be admitted to a neonatal intensive care unit (OR 2.02;
95% CI 1.11 – 3.66) and to have small head circumferences (OR 3.89;
95% CI 1.25 – 12.03) (Freeman et al., 2018). Most studies adjusted for
underlying maternal mental illness (Freeman et al., 2018; Sheehy et al.,
2019; Yonkers et al., 2017), which are also associatied with adverse
birth ouctomes (Grote et al., 2010; Jarde et al., 2016). A meta-analysis
did not find increased teratogenic risks, yielding an OR of 1.07 (95% CI
0.91 – 1.25) for cohort studies and of 1.27 (95% CI 0.69 – 2.32) for
case-control studies (Enato et al., 2011).
Considering the potential risks of the use of benzodiazepines, it is
important to have an overview of prescription patterns of benzodiaze-
pines and benzodiazepine-related drugs in the peripartum period,
which will be helpful in estimating the prevalence of benzodiazepine
usage and to explore future research priorities. This is considered re-
levant, as the use of prescription medication during pregnancy has in-
creased in the past decades (Bjorn et al., 2011; Ingstrup et al., 2018;
Mitchell et al., 2011; Smolina et al., 2015). In the present study, we
aimed to present population-based information on prescription patterns
of benzodiazepines and benzodiazepine-related drugs in the peripartum
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period over 19 years in Denmark. We further studied whether pre-
scription prevalence rates increased in accordance with trends observed
in other prescription medications.
2. Method
2.1. Study population
We conducted a population-based cohort study using Danish na-
tional registers. All individuals in Denmark have a unique personal civil
registration number that enables the individual-level linkage of in-
formation across nationwide registries. All pregnancies leading to live
birth(s) in Denmark between 1 January 1997 and 31 December 2015
(N= 1182,529) were identified from the Danish Medical Birth Registry
(Bliddal et al., 2018), since prescription data was available until 2016
and prevalence was studied until 12 months after delivery. The registry
contains data on the mother and child, such as parity, date of birth,
birth weight, length, sex, and gestational age of the offspring. We ex-
cluded 660 pregnancies by women aged <15 or >45 years. Further-
more, 27,052 pregnancies were excluded due to missing information in
gestational age or if gestational age was recorded as <22 weeks or >45
weeks. Thus, 1154,817 pregnancies were included in the analyses.
2.2. Assessment of prescription for benzodiazepine and benzodiazepine-
related drugs
Information on medication prescriptions in the peripartum period
was obtained from the linkage of study subjects to the National
Prescription Registry (Pottegard et al., 2017). The register contains
individual-level data on all prescribed drugs dispensed at all pharma-
cies in Denmark since 1995. Registered information includes the type of
drug, strength, quantity dispensed, and dispensing dates. The interna-
tional Anatomical Therapeutic Chemical (ATC) classification system
was used to code all medications. From April 1st, 2004 onwards, an
indication variable was also added. The prescriber, e.g., a general
practitioner or a hospital physician, may select an indication code from
a drop-down menu containing a list of indications, or they can include
the indication as free text, in which case no code is recorded
(Denmark Statistics, 2013). Women were considered as user of benzo-
diazepines or benzodiazepine-related drugs (hereinafter referred to as
benzodiazepines) if they claimed any drugs starting with ATC codes
N05BA, N05CD, and N05CF from 12 months prior to the pregnancy to
12 months following the pregnancy. We defined pregnancy from the
first day of the last menstrual period until delivery. We estimated the
start of pregnancy by subtracting gestational age from the birth date.
Since 1995, ultrasound measurements have been widely used to de-
termine gestational age in nearly all pregnancies (Jorgensen, 1999).
2.3. Assessment of psychiatric history
In this study, we also focused on women with a psychiatric history,
since treatment decisions are even more complex in this group (Ingstrup
et al., 2018). We defined previous psychiatric history as at least one in-
or outpatient treatment for psychiatric disorders or redeemed one
prescription for psychotropic medications (ATC codes N05 and N06) at
the time of 12 months before the index pregnancy. Information on
psychiatric history before pregnancy was extracted from the Danish
Psychiatric Central Research Register (Mors et al., 2011). It contains
data on all inpatient contacts since 1969 and from 1995 also outpatient
contacts. The International Classification of Diseases (ICD) codes, ver-
sion 8 (ICD-8) was used from 1977 to 1993 and ICD-10 from 1994 and
onwards. The following ICD codes were used to identify psychiatric
disorders: ICD-8 codes 290–315; ICD-10 codes F00–F99.
2.4. Treatment indications of benzodiazepine prescriptions
We investigated the treatment indications of benzodiazepine pre-
scriptions in a subset of women who gave birth to children from 2007 to
2015, due to substantial missing or unspecified indication codes during
2004–2005 in the Danish National Prescription Registry. Here, the
number of prescriptions is counted, and overall, 27,094 prescriptions
dispensed before pregnancy, 6820 during pregnancy and 16,574 after
pregnancy were included. We excluded the prescriptions with missing
or unspecified indications; 6898 (25.5%) before pregnancy, 2064
(30.3%) during pregnancy, and 3884 (23.4%) after pregnancy.
2.5. Ethics
Registries were linked, and personal data analyzed on Statistics
Denmark, where data was made available with encrypted personal in-
formation. This ensures that no individuals can be identified. In
Denmark, The Act on Processing of Personal Data does not require
ethical permission or obtained written informed consent for anon-
ymised retrospective registry studies. The present study has been ap-
proved by the Danish Data Protection Agency.
2.6. Statistical analysis
All data management and analyses were performed using Stata 15.0
(StataCorp, College Station, TX, USA). We analyzed dispensed benzo-
diazepine prescriptions in women during three periods: 12 months
leading to pregnancy, during pregnancy, and 12 months after preg-
nancy. We first examined the overall prevalence of benzodiazepine
prescriptions before, during, and after pregnancy. We allowed for ex-
posure to benzodiazepines several times during the study period. For
further explanation of the calculation of period prevalence, consider the
following example: woman A redeemed three prescriptions from 12
months before pregnancy to 12 months after pregnancy, one before
pregnancy, one during pregnancy, and another after pregnancy. She
will consequently contribute information in the calculation of period
prevalence before, during, and after pregnancy.
To determine whether patterns of prescribing of benzodiazepine
drugs changed over time, we used generalised estimating equations
with an identity link to estimate the adjusted 5-year risk difference
(Hanley et al., 2003), i.e., the difference in the proportion of women
redeeming benzodiazepines before, during, or after pregnancy from one
year to five years after. We treated calendar year as a continuous
variable (in years), and adjusted for age (<25, 25–34 or ≥35 years),
primiparity (yes/no), and socioeconomic status (lowest quartile, second
quartile, third quartile, or highest quartile) at the time of delivery in the
models. Since the pattern of benzodiazepine prescriptions may be in-
fluenced by previous psychiatric history, all the analyses were stratified
by previous psychiatric history.
We defined the following seven mutually exclusive benzodiazepine
groups: (1) prescriptions before pregnancy only; (2) prescriptions
during pregnancy only; (3) prescriptions after pregnancy only; (4)
prescriptions both before and during pregnancy; (5) prescriptions both
before and after pregnancy; (6) prescriptions both during and after
pregnancy; (7) prescriptions before, during, and after pregnancy. Note,
the number of womenwith benzodiazepine prescriptions was counted for
these analyses. In the analysis of the association between general
characteristics and discontinuation of a benzodiazepine during preg-
nancy, only women receiving benzodiazepine prescriptions before
pregnancy (i.e., group 1, 4, 5, and 7) were included, and binary logistic
regression models were used. The following characteristics were in-
cluded in the models: age at delivery, primiparity, socioeconomic
status, previous psychiatric history, hospital contact for psychiatric
disorders, and co-dispensing of other psychotropic medication (ATC
codes N05 and N06 excluding N05BA, N05CD, and N05CF; yes or no) in
the year before pregnancy, and calendar year at delivery (1997–2000,
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2001–2005, 2006–2010 or 2011–2015).
3. Results
Of 1154,817 pregnancies, 205,406 (17.8%) pregnancies were in
women with a psychiatric history 12 months before pregnancy. Table 1
presents the characteristics of the study subjects. Women with a psy-
chiatric history before pregnancy were older, were less often primi-
parous, and had lower socioeconomic status, compared to women with
no psychiatric history. Women with a psychiatric history more often
used other psychotropic medications and had more often hospital
contacts for psychiatric disorders in the year before pregnancy, as ex-
pected.
The prevalence of women with benzodiazepine prescriptions was
1.9% before pregnancy, 0.6% during pregnancy, and 1.3% after preg-
nancy. Prevalence specifically during pregnancy was 0.5% in the first
trimester, 0.3% in the second trimester, and 0.2% in the third trimester.
Among 6806 women using benzodiazepines during pregnancy, 4446
(65.3%) women did not receive benzodiazepine prescriptions in the
year preceding pregnancy (Table 2).
The most frequently prescribed drug was zopiclone before preg-
nancy, where this was oxazepam during and after pregnancy
(Supplementary Table 1). Benzodiazepines were most often prescribed
for sleeping problems (52.3%) in the peripartum period, followed by
anxiety disorder (40.6%) and panic disorder (4.7%) (Supplementary
Table 2). In women with a psychiatric history before pregnancy, the
prevalence of women with benzodiazepine prescriptions in the
peripartum period was approximately 5 to 6 times higher, compared to
women with no psychiatric history (Fig. 1).
Fig. 2 displays the percentage of women receiving benzodiazepine
prescriptions by calendar year. From 1997 to 2015, a significant de-
crease in the percentage of benzodiazepines prescribed to women with
a psychiatric history was observed before, during, and after pregnancy,
with an adjusted 5 year risk difference of −2.3% (95% CI −2.4 –
2.2%), −0.9% (95% CI −1.0% – 0.8%), and −1.5% (95% CI −1.6% –
1.4%), respectively. The decrease was less profound among women
with no psychiatric history, where the risk difference was −0.2 (95% CI
−0.2% – 0.2%) before pregnancy, −0.1% (95% CI −0.1% – 0.1%)
during pregnancy, and −0.2% (95% CI −0.2% – 0.2%) after preg-
nancy.
Among 22,043 women who were prescribed benzodiazepines before
pregnancy, 19,683 (89.3%) women discontinued this during pregnancy
(Table 2). This percentage was lower in women with a psychiatric
history (83.1%), compared to women with no psychiatric history
(97.1%). A higher percentage of women discontinuing benzodiazepines
during pregnancy was observed from 1997 to 2015. This increase was
more profound among women with a psychiatric history (Fig. 3).
Various characteristics were associated with benzodiazepine dis-
continuation (Fig. 4). Primiparity, higher socioeconomic status, and a
later calendar year of childbirth were associated with higher odds for
discontinuation during pregnancy. A higher age, a previous psychiatric
history, the use of other psychotropic medications, and hospital con-
tacts for psychiatric disorders in the year before pregnancy were asso-
ciated with lower odds for discontinuation during pregnancy.
Table 1
Characteristics of the study population.
Characteristics Women with psychiatric history a Women with no psychiatric history Total (N = 1154,817)
No prescription drug
(N = 930,291)
With prescription drug
(N = 19,120)
No prescription drug
(N = 186,576)
With prescription drug
(N = 18,830)
Age at conception (years)
15–24 22,084 (11.8) 1934 (10.3) 124,228 (13.4) 2930 (15.3) 151,176 (13.1)
25–34 119,776 (64.2) 11,525 (61.2) 651,921 (70.1) 12,796 (66.9) 796,018 (68.9)
35–45 44,716 (24.0) 5371 (28.5) 154,142 (16.6) 3394 (17.8) 207,623 (18.0)
Primiparous (%) 81,228 (43.5) 7872 (41.8) 420,794 (45.2) 8270 (43.3) 518,164 (44.9)
Socioeconomic status at conception
Lowest quartile 31,246 (16.8) 4763 (25.3) 146,912 (15.8) 3500 (18.3) 186,421 (16.1)
2nd quartile 43,874 (23.5) 5102 (27.1) 181,002 (19.5) 4547 (23.8) 234,525 (20.3)
3rd quartile 44,718 (24.0) 4025 (21.4) 238,100 (25.6) 4738 (24.8) 291,581 (25.3)
Highest quartile 48,731 (26.1) 3888 (20.6) 310,342 (33.4) 5656 (29.6) 368,617 (31.9)
Unknown 18,007 (9.7) 1052 (5.6) 53,935 (5.8) 679 (3.6) 73,673 (6.4)
Other psychotropic medications in the
year before pregnancy
32,984 (17.7) 7751 (41.2) 10,102 (1.1) 1872 (9.8) 52,709 (4.6)
Hospital contact for psychiatric
disorders in the year before
pregnancy
6120 (3.3) 2075 (11.0) 2983 (0.3) 632 (3.3) 11,810 (1.0)
Calendar year of childbirth
1997–2000 15,446 (8.3) 3386 (18.0) 227,272 (24.4) 6397 (33.5) 252,501 (21.9)
2001–2005 40,023 (21.5) 5429 (28.8) 261,328 (28.1) 5793 (30.3) 312,573 (27.1)
2006–2010 61,612 (33.0) 5587 (29.7) 238,950 (25.7) 4244 (22.2) 310,393 (26.9)
2011–2015 69,495 (37.2) 4428 (23.5) 202,741 (21.8) 2686 (14.1) 279,350 (24.2)
a Women with psychiatric history was defined as at least one hospital contact for psychiatric disorders or dispensing one psychotropic prescription before our
study period, i.e., 12 months prior to the index pregnancy.
Table 2
Prevalence of women with benzodiazepine prescriptions before, during, and after pregnancy.
Benzodiazepine prescriptions during perinatal period With psychiatric history (N = 205,406) With no psychiatric history (N = 949,411)
Before pregnancy only 8895 (4.3) 9087 (1.0)
During pregnancy only 1578 (0.8) 2425 (0.3)
After pregnancy only 4665 (2.3) 6796 (0.7)
Both before and during pregnancy 822 (0.4) 187 (<0.1)
Both before and after pregnancy 1337 (0.7) 364 (<0.1)
Both during and after pregnancy 280 (0.1) 163 (<0.1)
Both before, during, and after pregnancy 1253 (0.6) 98 (<0.1)
Figures are numbers of women (%).
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Fig. 1. The use of anxiolytics, hypnotics and sedatives, and benzodiazepine-related drugs in the year before, during pregnancy, or in the year following pregnancy.
Fig. 2. Number of deliveries in which the women received a dispensing for benzodiazepine and benzodiazepine-related drugs in the year before, during pregnancy or
in the year following pregnancy.
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4. Discussion
In this population-based study, we found that the prevalence of
benzodiazepine use before pregnancy is 1.9%, during pregnancy 0.6%,
and after pregnancy 1.3%. In women with a psychiatric history before
pregnancy, the prevalence was approximately 5 to 6 times higher than
in women without such a history.
4.1. Prevalence comparison
Benzodiazepine use in the peripartum period has been studied
worldwide, including Nordic countries. However, different time per-
iods, definitions of medication use, study subjects, and data collection
methods make it difficult to compare these findings directly. A popu-
lation-based study conducted in Sweden found a prevalence of 0.16%
for benzodiazepines and of 0.12% for benzodiazepine-related drugs in
the first trimester (Reis and Kallen, 2013). A Norwegian population-
based study found a prevalence of 1.8% before pregnancy, of 1.5%
during pregnancy and of 0.8% after pregnancy for benzodiazepines
(Riska et al., 2014). Outside the Nordic countries, higher prevalences
are observed in Europe (Ban et al., 2012; Hurault-Delarue et al., 2016;
Radojcic et al., 2017), and particularly in North America, with pre-
valences ranging from 1.8% to 3.9% (Bergman et al., 1992; Daw et al.,
2012; Hanley and Mintzes, 2014; Palmsten et al., 2015).
4.2. Change over time in prescriptions
Prescription drug use during pregnancy has increased over the past
decades (Bjorn et al., 2011; Ingstrup et al., 2018; Mitchell et al., 2011;
Smolina et al., 2015). However, benzodiazepine use during pregnancy
throughout the years has not been studied to a great extent. One po-
pulation-based study in Denmark studied the prescription rates of
benzodiazepine-related drugs and found an increase from 0.18% in
1997 to 0.23% in 2010 (Askaa et al., 2014). However, this study, using
the same registers, studied only benzodiazepine-related drugs, which is
used by only a maximum of 10% by all benzodiazepine users (Fig. 1).
The small increase of this class is obscured by the large decrease of
benzodiazepines in general. A study from the United States also found
an increase in benzodiazepine exposure from 0.3% in 2002 to 1.0% in
2009 (Martin et al., 2015). This is contrary to the findings from the
present study, where a decrease in the prevalence of prescriptions was
observed, especially in women with a psychiatric history. Many studies
have reported various adverse effects on the fetus from maternal ben-
zodiazepine use during pregnancy (Freeman et al., 2018; Ogawa et al.,
2018; Sheehy et al., 2019; Yonkers et al., 2017), which may have in-
creased awareness among women and their physicians, causing a de-
crease in prescriptions over the years. In the past, patients with anxiety
disorders were often treated with benzodiazepines, but recent guide-
lines do not recommend benzodiazepines as first choice treatment for
these indications (Bandelow et al., 2014). These patients are, therefore,
Fig. 3. Percentage of women with benzodiazepine dispensing in the year before
pregnancy discontinuation during pregnancy in Denmark, 1997–2015. Dotted
lines represent the 95% confidence intervals.
Fig. 4. The odds ratios of benzodiazepine discontinuation during pregnancy by characteristics (N=22,043). All the covariates were mutually adjusted in the models.
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treated more often with antidepressants instead of benzodiazepines
(Berney et al., 2008; Offidani et al., 2013), which may contribute to the
observed decrease in benzodiazepines in the past decades. We further
speculate that women with a history of treatment at psychiatric facil-
ities may get more information about the adverse effects of medication
during pregnancy from health care providers than women without a
psychiatric history, which would explain the differences in dis-
continuation between these groups.
4.3. Discontinuation of benzodiazepines during pregnancy
In the present study, approximately nine out of ten women dis-
continue benzodiazepines during pregnancy, a discontinuation pattern
comparable to other studies (Askaa et al., 2014; Riska et al., 2014),
which may be driven by not only a change in treatment guidelines
(Berney et al., 2008; Offidani et al., 2013), but also by fear of potential
adverse effects for the fetus (Arch, 2014; Einarson et al., 2001). The
percentage of women discontinuing during pregnancy increased in the
past years, especially among women with a psychiatric history. High
discontinuation rates during pregnancy are not shown by all studies
(Daw et al., 2012; Hanley and Mintzes, 2014; Palmsten et al., 2015).
These differences in prescription patterns may reflect differences in the
prevalence and/or severity of mental health problems (Steel et al.,
2014), but could also be due to differences in national guidelines,
prescribing behaviour of physicians, beliefs about medication use in the
population, and available medical facilities.
4.4. Strengths and limitations
Our data were obtained from national registers, covering the entire
Danish population. We studied over a million pregnancies and we are,
therefore, to our knowledge, one of the largest studies studying ben-
zodiazepine prescription patterns. However, there are some inbuilt
limitations to describe use of medications using register-based data.
First of all, we studied prescriptions for medication and not actual use.
Non-compliance may overestimate our results, however contrarily,
underestimation of the results may also have occurred, since women
may sporadically use medication of family members or friends.
Secondly, prescriptions are only captured from community pharmacies
and not during inpatient stays, which could have underestimated our
findings. However, if a woman was admitted, she would most likely be
prescribed medication afterward. In this case, she would have been
captured by using the prescription register. Further, we used the date of
dispensing to determine the date of use. However, it is possible that
women used the medication in a different trimester or peripartum
phase from when the medication was dispensed. Finally, we only in-
cluded pregnancies ending in live births. A recent study showed an
association between benzodiazepine exposure and risk of spontaneous
abortion during early pregnancy (Sheehy et al., 2019). Therefore, only
including live births may have consequences for the generalizability of
our findings.
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